Developer docs
API playgroundTry for free, no card

Search company profiles

Nucleus RadioPharma

Full company profile

uuid0000ahf

Namestring
Nucleus RadioPharma
Legal namestring
Nucleus RadioPharma
Websiteurl
nucleusrad.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Nucleus RadioPharma is a privately held, venture-backed contract development and manufacturing organization (CDMO) focused exclusively on radiopharmaceuticals for targeted radiotherapy and theranostic oncology applications. Founded in October 2022 by Eclipse Ventures and Mayo Clinic and headquartered in Rochester, Minnesota, the company was created to remove the manufacturing, supply-chain, and delivery bottlenecks that limit patient access to short half-life radiopharmaceuticals. Its customers are pharmaceutical and biotech companies developing targeted radiotherapies and theranostics; the company explicitly positions as a "collaborator, not competitor" by holding no internal drug development program that could conflict with client engagements.

The platform is an isotope-flexible, end-to-end radiopharmaceutical CDMO spanning four operational modules: LABS (R&D, including chelation, radiolabeling, analytical method development, formulation, and stability planning), Supply Chain (specialty logistics with proprietary IATA 7A/Type A shipping packages and a real-time GPS-tracking mobile app), Manufacturing (clinical through commercial dose manufacturing and fill/finish), and Quality & Regulatory (electronic QMS aligned to 21 CFR 211 and ICH Q10, plus NRC, DOT, ATF, and HAZMAT licensing). Nucleus is licensed to handle an unusually broad isotope portfolio including Lu-177, Ac-225, Cu-61/64/67, Pb-212, Tb-149/152/155/161, Y-90, I-131, and others. Production is anchored at a Rochester, MN facility (~10K starting capacity scaling to ~50K vials/year) with a 47,000+ sq ft Springhouse Innovation Park, PA expansion site under construction (planned 2028, ~450K vials/year, aligned with EU Annex 1 and ISO 13408-6). A flagship commercial manufacturing agreement with Clarity Pharmaceuticals reserves 50,000 doses/year in Rochester and 600,000 doses/year in Springhouse for Cu-64 SAR-bisPSMA, contingent on FDA NDA approval.

The company is also extending beyond pure CDMO services into delivery hardware via a first-of-its-kind shielded theranostic infusion system for Lu-177 and Ac-225 (regulatory submission targeted Fall 2025, commercial launch 2026). Nucleus has raised approximately $106M across seed (2022), Series A (2023, co-led by Eclipse and GE Healthcare with Mayo Clinic, Fox Chase, Mercy Health, University of Missouri, Echo Global Logistics, and Granger), an AstraZeneca-led Series A extension (2024), and a $50M OrbiMed financing (April 2026). The board and leadership combine a former FDA Commissioner (CEO Stephen Hahn), Mayo Clinic's former Chair of Nuclear Medicine (CSO/Geoffrey Johnson), and senior operations executives drawn from Genentech/Roche, Foundation Medicine, Eli Lilly, and AstraZeneca. AstraZeneca holds a board seat.

Short descriptiontext

Nucleus RadioPharma is a radiopharmaceutical CDMO serving pharma and biotech developers of targeted radiotherapies and theranostics, offering isotope-flexible end-to-end development, manufacturing, logistics, and regulatory services from facilities in Rochester, MN and Springhouse, PA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDavidson, United States
HQ citystring
Davidson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical manufacturing, contract development services, radiolabeling development, isotope supply logistics, theranostic CDMO
Industry2 codes
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Radiopharmaceutical Contract Manufacturing (CDMO)
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Development & Manufacturing (CDMO) services
TypeProfessional Services
Description

End-to-end CDMO revenue stream covering radiolabeling development, chelation, analytical method development, Phase 0–III clinical manufacturing, technology transfer, and commercial dose manufacturing (fill/finish). Customers pay for project-based and ongoing manufacturing capacity at Rochester, MN (10K–50K doses/year) and Springhouse, PA (~450K doses/year at full capacity).

nucleusrad.com
2Isotope supply and specialty radiopharmaceutical logistics
TypeManaged Services
Description

Revenue stream from isotope sourcing agreements with alpha and beta emitter suppliers plus specialty logistics (custom IATA 7A/Type A packages with proprietary real-time GPS tracking app). Provides isotope supply redundancy and just-in-time distribution to hospitals and destination medical centers.

nucleusrad.com
3Quality, regulatory and compliance services
TypeProfessional Services
Description

Regulatory and quality support aligned with cGMP expectations including FDA, NRC and USDOT requirements, supported by electronic QMS across the product lifecycle. Bundled within CDMO engagements.

nucleusrad.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nucleus RadioPharma is an end-to-end contract development and manufacturing organization (CDMO) partner dedicated to building clinical and commercial supply chains for targeted radiotherapies and theranostics. The company provides flexible radiopharmaceutical CDMO services across the lifecycle—from early development and pre-clinical research through Phase 0–III clinical manufacturing and commercialization—via an operational Rochester, MN facility and a planned Springhouse, PA expansion site. It operates as a non-competing collaborator (no internal drug development), with an unusually broad, isotope-flexible manufacturing platform, proprietary GPS-tracked specialty logistics, and is also developing a first-of-its-kind shielded theranostic infusion system.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Rochester facility starting capacity 10K product vials/year, scaling to 40-50K/year; Springhouse PA facility ~450K vials/year at full capacity
+4 more records
Product overview1 text field

Nucleus RadioPharma offers a unified full-service radiopharmaceutical CDMO platform, organized around four core service modules—LABS (R&D), Supply Chain, Manufacturing, and Quality & Regulatory—that together support clients from early development through commercialization. These capabilities are delivered through two facility footprints: an operational Rochester, MN site (10K starting capacity scaling to ~50K doses/year) and a planned Springhouse Innovation Park, PA expansion site (~450K doses/year). Industry-specific Pharma and Bio Tech solutions tailor the offering to client segments, and the company is also developing the Theranostic Shielded Infusion System—a first-of-its-kind shielded infusion device for Lu-177 and Ac-225 therapies—to address workflow gaps in radiopharmaceutical delivery.

Product and service2 records
1Full-Service Radiopharmaceutical CDMO
CategoryContract Development & Manufacturing (CDMO)
2Theranostic Shielded Infusion System
CategoryHardware product (medical device, in development)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-15
Description

Nucleus RadioPharma announced a Strategic Alliance with Thermo Fisher Scientific to advance radiopharmaceutical development and clinical execution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-05
Description

Nucleus RadioPharma and BWXT Medical entered a Master Purchase and Supply Agreement for critical radiopharmaceutical isotopes, securing isotope supply redundancy for Nucleus's manufacturing operations.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Clarity Pharmaceuticals signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for the production of 64Cu-SAR-bisPSMA, a next-generation diagnostic imaging agent for prostate cancer detection. Covers Rochester, MN facility (50,000 doses/year) and planned Springhouse, PA facility (600,000 doses/year opening 2028), enabling nationwide US distribution and expansion to select international markets including Europe, pending Phase III AMPLIFY/CLARIFY trial success and FDA NDA approval.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

SHINE Technologies is collaborating with Blue Earth Therapeutics and Nucleus RadioPharma on Lutetium-177 supply for targeted cancer treatments (referenced in Lutetium-177 industry research).

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-10-12
Description

Mayo Clinic co-created and provided seed funding for Nucleus RadioPharma to develop radiopharmaceuticals for cancer treatment. Mayo Clinic's former Chair of Nuclear Medicine, Dr. Geoffrey Johnson, is co-founder and CSO; Manu Nair (Associate Chief Business Development Officer at Mayo Clinic) serves on Nucleus's Board of Directors.

Strategic tierMinorTypeOthers
Description

Chris McDonald, Global Head of Technical Operations at Kite Pharma (Gilead), serves on Nucleus RadioPharma's Board of Directors. Relationship is primarily board-level executive overlap rather than an operational commercial partnership.

Strategic tierMinorTypeOthers
Description

Stephen Hahn, former CEO of Harbinger Health, now serves as CEO and Board Member at Nucleus RadioPharma. Relationship is executive-level rather than commercial.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Early-stage radiopharmaceutical biotech developing targeted alpha and beta therapies; representative of the biotech customer segment Nucleus targets with its Bio Tech CDMO solutions.

TypeBroad incumbent
Description

One of the largest PET and SPECT radiopharmaceutical manufacturing and distribution networks in the U.S. and globally; competes directly with Nucleus for pharma/biotech CDMO contracts and offers a broad portfolio rather than a single-isotope specialty.

TypeBroad incumbent
Description

Vertically integrated radiopharmaceutical company with both proprietary products (e.g., Pylarify, Definity) and established manufacturing/distribution infrastructure; competes with Nucleus both for CDMO clients and for downstream hospital contracts.

TypeDirect peer
Description

Global nuclear medicine CDMO operating large-scale PET, SPECT, and therapeutic radiopharmaceutical manufacturing; a directly comparable radiopharma CDMO peer with broad isotope capability similar to Nucleus's platform.

TypeBroad incumbent
Description

Operates one of the largest U.S. radiopharma distribution and manufacturing networks through its Nuclear & Precision Health Solutions unit; competes with Nucleus on commercial fill/finish and distribution for radiopharmaceuticals.

TypeBroad incumbent
Description

Manufactures and distributes PET tracers and radiopharmaceuticals globally and is a Nucleus investor/board-affiliated partner; a broad incumbent that both overlaps with and accelerates Nucleus's reach.

TypeDirect peer
Description

Belgian provider of radiopharma production solutions, including cyclotrons, hot cells, and contract manufacturing; a directly comparable equipment-and-services CDMO peer serving radiopharma developers globally.

TypeEmerging player
Description

Developer of diagnostic and therapeutic radiopharmaceuticals (e.g., Illuccix) with growing in-house manufacturing and external CDMO relationships; a peer on the demand side for radiopharma CDMO capacity and a possible direct competitor for theranostic manufacturing.

TypeEmerging player
Description

Supplies medical isotopes and is a Nucleus supply partner; comparable as a vertically integrated radiopharma manufacturer, though more focused on isotope production than finished-dose CDMO services.

TypeEmerging player
Description

Actinium-225-focused radiopharma developer acquired by BMS for $4.1B; a peer on the demand side for Ac-225 manufacturing capacity and a potential long-term CDMO customer of Nucleus's platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nucleus RadioPharma

Radiopharmaceutical Contract Manufacturing (CDMO)nucleusrad.com

Nucleus RadioPharma is a radiopharmaceutical CDMO serving pharma and biotech developers of targeted radiotherapies and theranostics, offering isotope-flexible end-to-end development, manufacturing, logistics, and regulatory services from facilities in Rochester, MN and Springhouse, PA.

What Nucleus RadioPharma does

Nucleus RadioPharma is a privately held, venture-backed contract development and manufacturing organization (CDMO) focused exclusively on radiopharmaceuticals for targeted radiotherapy and theranostic oncology applications. Founded in October 2022 by Eclipse Ventures and Mayo Clinic and headquartered in Rochester, Minnesota, the company was created to remove the manufacturing, supply-chain, and delivery bottlenecks that limit patient access to short half-life radiopharmaceuticals. Its customers are pharmaceutical and biotech companies developing targeted radiotherapies and theranostics; the company explicitly positions as a "collaborator, not competitor" by holding no internal drug development program that could conflict with client engagements.

The platform is an isotope-flexible, end-to-end radiopharmaceutical CDMO spanning four operational modules: LABS (R&D, including chelation, radiolabeling, analytical method development, formulation, and stability planning), Supply Chain (specialty logistics with proprietary IATA 7A/Type A shipping packages and a real-time GPS-tracking mobile app), Manufacturing (clinical through commercial dose manufacturing and fill/finish), and Quality & Regulatory (electronic QMS aligned to 21 CFR 211 and ICH Q10, plus NRC, DOT, ATF, and HAZMAT licensing). Nucleus is licensed to handle an unusually broad isotope portfolio including Lu-177, Ac-225, Cu-61/64/67, Pb-212, Tb-149/152/155/161, Y-90, I-131, and others. Production is anchored at a Rochester, MN facility (~10K starting capacity scaling to ~50K vials/year) with a 47,000+ sq ft Springhouse Innovation Park, PA expansion site under construction (planned 2028, ~450K vials/year, aligned with EU Annex 1 and ISO 13408-6). A flagship commercial manufacturing agreement with Clarity Pharmaceuticals reserves 50,000 doses/year in Rochester and 600,000 doses/year in Springhouse for Cu-64 SAR-bisPSMA, contingent on FDA NDA approval.

The company is also extending beyond pure CDMO services into delivery hardware via a first-of-its-kind shielded theranostic infusion system for Lu-177 and Ac-225 (regulatory submission targeted Fall 2025, commercial launch 2026). Nucleus has raised approximately $106M across seed (2022), Series A (2023, co-led by Eclipse and GE Healthcare with Mayo Clinic, Fox Chase, Mercy Health, University of Missouri, Echo Global Logistics, and Granger), an AstraZeneca-led Series A extension (2024), and a $50M OrbiMed financing (April 2026). The board and leadership combine a former FDA Commissioner (CEO Stephen Hahn), Mayo Clinic's former Chair of Nuclear Medicine (CSO/Geoffrey Johnson), and senior operations executives drawn from Genentech/Roche, Foundation Medicine, Eli Lilly, and AstraZeneca. AstraZeneca holds a board seat.

Nucleus RadioPharma firmographics

Firmographics
Name
Nucleus RadioPharma
Legal name
Nucleus RadioPharma
Website
https://nucleusrad.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Nucleus RadioPharma is a radiopharmaceutical CDMO serving pharma and biotech developers of targeted radiotherapies and theranostics, offering isotope-flexible end-to-end development, manufacturing, logistics, and regulatory services from facilities in Rochester, MN and Springhouse, PA.
Ownership category
akta.pro rank

Nucleus RadioPharma industry classification

Industry
Product category
Radiopharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
akta.pro industry
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Radiopharmaceutical manufacturing
  • Contract development services
  • Radiolabeling development
  • Isotope supply logistics
  • Theranostic CDMO

Where Nucleus RadioPharma is headquartered

Location

Headquarters

HQ city
Davidson
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nucleus RadioPharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development & Manufacturing (CDMO) services: End-to-end CDMO revenue stream covering radiolabeling development, chelation, analytical method development, Phase 0–III clinical manufacturing, technology transfer, and commercial dose manufacturing (fill/finish). Customers pay for project-based and ongoing manufacturing capacity at Rochester, MN (10K–50K doses/year) and Springhouse, PA (~450K doses/year at full capacity).
  2. Isotope supply and specialty radiopharmaceutical logistics: Revenue stream from isotope sourcing agreements with alpha and beta emitter suppliers plus specialty logistics (custom IATA 7A/Type A packages with proprietary real-time GPS tracking app). Provides isotope supply redundancy and just-in-time distribution to hospitals and destination medical centers.
  3. Quality, regulatory and compliance services: Regulatory and quality support aligned with cGMP expectations including FDA, NRC and USDOT requirements, supported by electronic QMS across the product lifecycle. Bundled within CDMO engagements.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels3 records

Nucleus RadioPharma product offering

Product offering

Core offering

Nucleus RadioPharma is an end-to-end contract development and manufacturing organization (CDMO) partner dedicated to building clinical and commercial supply chains for targeted radiotherapies and theranostics. The company provides flexible radiopharmaceutical CDMO services across the lifecycle—from early development and pre-clinical research through Phase 0–III clinical manufacturing and commercialization—via an operational Rochester, MN facility and a planned Springhouse, PA expansion site. It operates as a non-competing collaborator (no internal drug development), with an unusually broad, isotope-flexible manufacturing platform, proprietary GPS-tracked specialty logistics, and is also developing a first-of-its-kind shielded theranostic infusion system.

Product overview

Nucleus RadioPharma offers a unified full-service radiopharmaceutical CDMO platform, organized around four core service modules—LABS (R&D), Supply Chain, Manufacturing, and Quality & Regulatory—that together support clients from early development through commercialization. These capabilities are delivered through two facility footprints: an operational Rochester, MN site (10K starting capacity scaling to ~50K doses/year) and a planned Springhouse Innovation Park, PA expansion site (~450K doses/year). Industry-specific Pharma and Bio Tech solutions tailor the offering to client segments, and the company is also developing the Theranostic Shielded Infusion System—a first-of-its-kind shielded infusion device for Lu-177 and Ac-225 therapies—to address workflow gaps in radiopharmaceutical delivery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Full-Service Radiopharmaceutical CDMO
  • Theranostic Shielded Infusion System

Quantifiable outcome

  • Rochester facility starting capacity 10K product vials/year, scaling to 40-50K/year; Springhouse PA facility ~450K vials/year at full capacity
  • +4 more outcomes

Companies that use Nucleus RadioPharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Nucleus RadioPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Nucleus RadioPharma partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • Thermo Fisher ScientificflagshipStrategic or Co-development Partner · 15 June 2026Nucleus RadioPharma announced a Strategic Alliance with Thermo Fisher Scientific to advance radiopharmaceutical development and clinical execution.
  • BWXT MedicalcoreStrategic or Co-development Partner · 5 June 2026Nucleus RadioPharma and BWXT Medical entered a Master Purchase and Supply Agreement for critical radiopharmaceutical isotopes, securing isotope supply redundancy for Nucleus's manufacturing operations.
  • Clarity PharmaceuticalsflagshipStrategic or Co-development Partner · 14 April 2026Clarity Pharmaceuticals signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for the production of 64Cu-SAR-bisPSMA, a next-generation diagnostic imaging agent for prostate cancer detection. Covers Rochester, MN facility (50,000 doses/year) and planned Springhouse, PA facility (600,000 doses/year opening 2028), enabling nationwide US distribution and expansion to select international markets including Europe, pending Phase III AMPLIFY/CLARIFY trial success and FDA NDA approval.
  • SHINE TechnologiescoreTechnology or Integration · 1 January 2024SHINE Technologies is collaborating with Blue Earth Therapeutics and Nucleus RadioPharma on Lutetium-177 supply for targeted cancer treatments (referenced in Lutetium-177 industry research).
  • Mayo ClinicflagshipStrategic or Co-development Partner · 12 October 2022Mayo Clinic co-created and provided seed funding for Nucleus RadioPharma to develop radiopharmaceuticals for cancer treatment. Mayo Clinic's former Chair of Nuclear Medicine, Dr. Geoffrey Johnson, is co-founder and CSO; Manu Nair (Associate Chief Business Development Officer at Mayo Clinic) serves on Nucleus's Board of Directors.
  • Kite Pharma, a Gilead CompanyminorOthersChris McDonald, Global Head of Technical Operations at Kite Pharma (Gilead), serves on Nucleus RadioPharma's Board of Directors. Relationship is primarily board-level executive overlap rather than an operational commercial partnership.
  • Harbinger HealthminorOthersStephen Hahn, former CEO of Harbinger Health, now serves as CEO and Board Member at Nucleus RadioPharma. Relationship is executive-level rather than commercial.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Nucleus RadioPharma competitors and assessment

Company assessment

Emerging players

  • Abdera Therapeutics: Early-stage radiopharmaceutical biotech developing targeted alpha and beta therapies; representative of the biotech customer segment Nucleus targets with its Bio Tech CDMO solutions.
  • Telix Pharmaceuticals: Developer of diagnostic and therapeutic radiopharmaceuticals (e.g., Illuccix) with growing in-house manufacturing and external CDMO relationships; a peer on the demand side for radiopharma CDMO capacity and a possible direct competitor for theranostic manufacturing.
  • BWXT Medical: Supplies medical isotopes and is a Nucleus supply partner; comparable as a vertically integrated radiopharma manufacturer, though more focused on isotope production than finished-dose CDMO services.
  • RayzeBio (a Bristol Myers Squibb company): Actinium-225-focused radiopharma developer acquired by BMS for $4.1B; a peer on the demand side for Ac-225 manufacturing capacity and a potential long-term CDMO customer of Nucleus's platform.

Broad incumbents

  • PETNET Solutions (Siemens Healthineers): One of the largest PET and SPECT radiopharmaceutical manufacturing and distribution networks in the U.S. and globally; competes directly with Nucleus for pharma/biotech CDMO contracts and offers a broad portfolio rather than a single-isotope specialty.
  • Lantheus Holdings: Vertically integrated radiopharmaceutical company with both proprietary products (e.g., Pylarify, Definity) and established manufacturing/distribution infrastructure; competes with Nucleus both for CDMO clients and for downstream hospital contracts.
  • Cardinal Health (Nuclear & Precision Health Solutions): Operates one of the largest U.S. radiopharma distribution and manufacturing networks through its Nuclear & Precision Health Solutions unit; competes with Nucleus on commercial fill/finish and distribution for radiopharmaceuticals.
  • GE HealthCare (Pharmaceutical Diagnostics): Manufactures and distributes PET tracers and radiopharmaceuticals globally and is a Nucleus investor/board-affiliated partner; a broad incumbent that both overlaps with and accelerates Nucleus's reach.

Direct peers

  • Curium Pharma: Global nuclear medicine CDMO operating large-scale PET, SPECT, and therapeutic radiopharmaceutical manufacturing; a directly comparable radiopharma CDMO peer with broad isotope capability similar to Nucleus's platform.
  • IBA RadioPharma Solutions: Belgian provider of radiopharma production solutions, including cyclotrons, hot cells, and contract manufacturing; a directly comparable equipment-and-services CDMO peer serving radiopharma developers globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Nucleus RadioPharma social profiles

Digital presence

Nucleus RadioPharma compliance and trust

Trust signal

Compliance6 records

Nucleus RadioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nucleus RadioPharma leadership team

Management profile

Number of profiles

Profiles6 records

Nucleus RadioPharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nucleus RadioPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucleus RadioPharma

What does Nucleus RadioPharma do?

Nucleus RadioPharma is an end-to-end contract development and manufacturing organization (CDMO) partner dedicated to building clinical and commercial supply chains for targeted radiotherapies and theranostics. The company provides flexible radiopharmaceutical CDMO services across the lifecycle—from early development and pre-clinical research through Phase 0–III clinical manufacturing and commercialization—via an operational Rochester, MN facility and a planned Springhouse, PA expansion site. It operates as a non-competing collaborator (no internal drug development), with an unusually broad, isotope-flexible manufacturing platform, proprietary GPS-tracked specialty logistics, and is also developing a first-of-its-kind shielded theranostic infusion system.

Is Nucleus RadioPharma a public or private company?

Nucleus RadioPharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nucleus RadioPharma founded?

Nucleus RadioPharma was founded in 2022. It employs 51 to 100 people.

Where is Nucleus RadioPharma based?

Nucleus RadioPharma is headquartered in Davidson, United States, in the North America region.

How does Nucleus RadioPharma make money?

Three revenue lines are on record. Contract Development & Manufacturing (CDMO) services are the primary driver. The others are isotope supply and specialty radiopharmaceutical logistics and quality, regulatory and compliance services.

Who are Nucleus RadioPharma's main competitors?

Emerging players on record are Abdera Therapeutics, Telix Pharmaceuticals, BWXT Medical and RayzeBio (a Bristol Myers Squibb company). Broad incumbents are PETNET Solutions (Siemens Healthineers), Lantheus Holdings, Cardinal Health (Nuclear & Precision Health Solutions) and GE HealthCare (Pharmaceutical Diagnostics). Direct peers are Curium Pharma and IBA RadioPharma Solutions.

Does Nucleus RadioPharma have an API?

No public API is recorded for Nucleus RadioPharma.

What industry is Nucleus RadioPharma in?

Nucleus RadioPharma's product category is Radiopharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyPerceptive, Nucleus partner to support radiopharmaceutical developmentPerceptive Discovery and Nucleus RadioPharma announced a non-exclusive strategic partnership to help radiopharmaceutical developers move from target validation to clinical manufacturing. The companies will direct qualified customer opportunities to each other and maintain independent operations. They plan to evaluate performance and expand the partnership based on customer demand.Rochester Post BulletinHealth tech firms are finally starting to grow in RochesterRochester, Minnesota is finally seeing the results of its multi-decade effort to build a health tech ecosystem, with multiple companies now growing and hiring after years of infrastructure investment. Key companies include Nucleus RadioPharma, which recently opened research and manufacturing facilities for radiopharmaceutical drugs, and United Therapeutics Corp., which is building a $110 million facility to produce gene-edited pig organs for transplantation. Local economic development officials estimate southeastern Minnesota now has 60 to 100 health science companies, though workforce challenges in specialized fields like radiochemistry and nuclear physics remain a bottleneck for continued growth.TcbmagNucleus RadioPharma Secures $50 Million in FinancingNucleus RadioPharma secured $50 million from OrbiMed to expand manufacturing at its Rochester facility and build a new site near Philadelphia. The company aims to create a regional network for radiopharmaceuticals, with the Philadelphia hub planned to be operational by 2028.PR NewswireClarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharmaClarity Pharmaceuticals has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for the production of 64Cu-SAR-bisPSMA, a next-generation diagnostic imaging agent for prostate cancer detection. The agreement covers Nucleus RadioPharma's existing facility in Rochester, Minnesota (50,000 doses/year) and a planned facility in Spring House, Pennsylvania opening in 2028 (600,000 doses/year), enabling nationwide US distribution and expansion to select international markets including Europe. The agreement represents a key step in Clarity's manufacturing buildout ahead of the product's anticipated commercial launch, pending successful completion of Phase III registrational trials AMPLIFY and CLARIFY and subsequent FDA NDA approval.PR Newswire APACClarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharmaClarity Pharmaceuticals signed a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA, effective April 14, 2026. The agreement covers Nucleus's Rochester, Minnesota facility, capable of 50,000 doses annually, and a planned Spring House, Pennsylvania site opening in 2028 for up to 600,000 doses. The deal supports Clarity's commercial launch after Phase III trials.EIN PresswireFORMER FDA COMMISSIONER DR. STEPHEN HAHN JOINS LAMASSU BIOTECH BOARD OF DIRECTORSStephen Hahn, former FDA commissioner, joined Lamassu Biotech's board of directors as a strategic advisor. He will support the company's MDM2 inhibitor SA53, which is in Phase 1/2a trials and has shown a favorable safety profile. The therapy could apply to up to 50% of cancer cases, including rare cancers like sarcoma.BioSpaceRadiopharmaceutical Sector Shapes Supply Chain Around Fast-Decaying ProductsRadiopharmaceutical companies are structuring their supply chains around the challenge of delivering short-lived radioactive medicines before they decay, with NorthStar shipping actinium-225 globally from its Wisconsin facility while Nucleus RadioPharma expands from its Mayo Clinic-connected base in Rochester, Minnesota. The industry relies on air transport, private planes, and overland shipping within six to eight hours of facilities, with companies building tracking technology and time buffers to ensure medicines arrive before patient appointments. Nucleus plans to add an East Coast facility outside Philadelphia and a West Coast site in three to five years, and is considering Asian partnerships to address the geographic challenges of radiopharmaceutical distribution.Precedence ResearchRadiopharmaceutical CDMO Market Size to Hit USD 8.50 Billion by 2035The global radiopharmaceutical CDMO market was valued at USD 3.24 billion in 2025 and is projected to reach USD 8.50 billion by 2035, growing at a CAGR of 10.12%, driven by rising nuclear medicine demand, oncology-focused innovation, and increased outsourcing of radioactive drug development and manufacturing. North America led the market with a 49% share in 2025, while the Asia Pacific region is expected to grow at the fastest rate through 2035, supported by government investments in domestic isotope production and expanding clinical trial activity. Recent developments include Lantheus's acquisition of Evergreen Theragnostics for up to $1 billion and Nucleus RadioPharma's launch of a new theranostic infusion system, reflecting active consolidation and innovation in the sector.VentureRadarNew Funding Rounds in cdmoThe article lists multiple recent funding rounds for various contract development and manufacturing organizations (CDMOs) and biotech companies, including Phlow raising $37M and Sai Parenterals securing ₹50 Crore. It also highlights investments in specialized sectors such as aging treatments by Primo Biotechnology and radiopharmaceuticals by Nucleus RadioPharma with AstraZeneca support. The content serves as a digest of venture capital activity across the healthcare and pharmaceutical manufacturing industries.NucleusradFull-Service CDMO For Targeted RadiotherapiesNucleus RadioPharma is positioning itself as a full-service Contract Development and Manufacturing Organization (CDMO) dedicated to targeted radiotherapies, highlighting its current facility in Rochester, MN and planned expansions in Pennsylvania and Arizona. The company aims to address supply chain bottlenecks in the radiopharmaceutical sector by offering scalable manufacturing capacity and R&D services to innovators developing radioligand therapies.